text: <unk>  is an anti neoplastic that is FDA approved for the treatment of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality..   Common adverse reactions include abdominal pain,  nausea, myalgia, asthenia, headache, bladder pain, cystitis, dysuria,  hematuria, incontinence, increased frequency of urination, pain in urethra, burning sensation,  malaise.
option_0: Valrubicin
option_1: Pirarubicin
option_2: Epirubicin
option_3: Amrubicin
option_4: Aclarubicin
option_5: Idarubicin hydrochloride
option_6: Epirubicin hydrochloride
option_7: Zorubicin